Visualization of fibroblast activation using

Atrial fibrillation FAPI fibroblast activation positron emission tomography (PET) pulmonary vein isolation (PVI) pulse field ablation (PFA)

Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 13 11 2022
accepted: 11 01 2023
medline: 21 1 2024
pubmed: 21 1 2024
entrez: 20 1 2024
Statut: ppublish

Résumé

Pulsed-field ablation (PFA) is a novel ablation modality for atrial fibrillation (AF) ablating myocardium by electroporation without tissue-heating. With its different mechanism of tissue ablation, it is assumed that lesion creation is divergent to thermal energy sources. 26 patients (15 PFA, 11 CBA) underwent Patient characteristics were comparable between groups. In PFA, focal FAPI uptake was only observed in 3/15 (20%) patients, whereas in the CBA cohort, 10/11 (90.9%) patients showed atrial visual uptake. We observed lower values of SUV Tissue response with respect to fibroblast activation seems to be less pronounced in PFA compared to established thermal ablation systems. This functional assessment might contribute to a better understanding of lesion formation in thermal and PFA ablation potentially contributing to better safety outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Pulsed-field ablation (PFA) is a novel ablation modality for atrial fibrillation (AF) ablating myocardium by electroporation without tissue-heating. With its different mechanism of tissue ablation, it is assumed that lesion creation is divergent to thermal energy sources.
METHODS METHODS
26 patients (15 PFA, 11 CBA) underwent
RESULTS RESULTS
Patient characteristics were comparable between groups. In PFA, focal FAPI uptake was only observed in 3/15 (20%) patients, whereas in the CBA cohort, 10/11 (90.9%) patients showed atrial visual uptake. We observed lower values of SUV
CONCLUSION CONCLUSIONS
Tissue response with respect to fibroblast activation seems to be less pronounced in PFA compared to established thermal ablation systems. This functional assessment might contribute to a better understanding of lesion formation in thermal and PFA ablation potentially contributing to better safety outcomes.

Identifiants

DOI: 10.1007/s12350-023-03220-8 PMID: 38245148
pubmed: 38245148
pii: S1071-3581(24)00126-0
doi: 10.1007/s12350-023-03220-8
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2018-2028

Informations de copyright

Copyright © 2022 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology.

Auteurs

Jana Kupusovic (J)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany; Department of Cardiology and Vascular Medicine, University Hospital Frankfurt, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Lukas Kessler (L)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Florian Bruns (F)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany; Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.

Jan-Eric Bohnen (JE)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Stephan G Nekolla (SG)

Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.

Manuel M Weber (MM)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Anna Lauenroth (A)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Manuel Rattka (M)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Ken Hermann (K)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Dobromir Dobrev (D)

Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany; Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA; Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, QC, Canada.

Tienush Rassaf (T)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Reza Wakili (R)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany; Department of Cardiology and Vascular Medicine, University Hospital Frankfurt, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.

Christoph Rischpler (C)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany; Department of Nuclear Medicine, Klinikum Stuttgart, Kriegsbergstr. 60, 70174, Stuttgart, Germany. Electronic address: c.rischpler@klinikum-stuttgart.de.

Johannes Siebermair (J)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany; Krankenhaus Goettlicher Heiland, Dornbacher Strasse. 20-30, 1170, Vienna, Austria.

Classifications MeSH